We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Immuron is a biotechnology business based in Australia. Immuron shares (IMC) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Immuron has a trailing 12-month revenue of around $356,431. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
| 52-week range | $0.076 - $0.17 |
|---|---|
| 50-day moving average | $0.1036 |
| 200-day moving average | $0.1168 |
| Target price | $19.26 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.077
| 1 week (2022-06-22) | -14.44% |
|---|---|
| 1 month (2022-05-30) | -23.00% |
| 3 months (2022-03-30) | -30.00% |
| 6 months (2021-12-30) | -26.67% |
| 1 year (2021-06-30) | -51.88% |
|---|---|
| 2 years (2020-06-30) | -70.38% |
| 3 years (2019-06-28) | -35.83% |
| 5 years (2017-06-29) | -71.48% |
| Revenue TTM | $356,431 |
|---|---|
| Gross profit TTM | $-665,060 |
| Return on assets TTM | -10.75% |
| Return on equity TTM | -16.91% |
| Profit margin | 0% |
| Book value | 0.106 |
| Market capitalisation | $18.2 million |
TTM: trailing 12 months
We're not expecting Immuron to pay a dividend over the next 12 months.
Immuron 's shares were split on a 1:40 basis on 17 November 2014. So if you had owned 40 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Immuron shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immuron shares which in turn could have impacted Immuron 's share price.
Over the last 12 months, Immuron 's shares have ranged in value from as little as $0.076 up to $0.17. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Immuron 's is 1.6131. This would suggest that Immuron 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
